Literature DB >> 22795544

Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis.

Te-Wei Chu1, Jiyuan Yang, Jindřich Kopeček.   

Abstract

A hybrid biomimetic system comprising high-molecular-weight, linear copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA) grafted with multiple Fab' fragments of anti-CD20 monoclonal antibody (mAb) was synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization followed by attachment of Fab' fragments via thioether bonds. Exposure of human non-Hodgkin's lymphoma (NHL) Raji B cells to the multivalent conjugates resulted in crosslinking of CD20 receptors and commencement of apoptosis. Five conjugates with varying molecular weight and valence (amount of Fab' per polymer chain) were synthesized. One of the copolymers contained enzyme degradable peptide sequences (GFLG) in the backbone. The multivalency led to higher avidity and apoptosis induction compared to unconjugated whole mAb. Time-dependent studies showed that the cytotoxicity of conjugates exhibited a slower onset at shorter exposure times than mAb hyper-crosslinked with a secondary Ab; however, at longer time intervals the HPMA copolymer conjugates achieved significantly higher biological efficacies. In addition, study of the relationship between the structure of conjugates and Raji B cell apoptosis revealed that both valency and polymer molecular weight influenced biological activities, while insertion of peptide sequences into the backbone was not a factor in vitro.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795544      PMCID: PMC3572842          DOI: 10.1016/j.biomaterials.2012.06.024

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  39 in total

1.  A ninhydrin-based assay to quantitate the total protein content of tissue samples.

Authors:  B Starcher
Journal:  Anal Biochem       Date:  2001-05-01       Impact factor: 3.365

Review 2.  A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Authors:  Arturo Molina
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

3.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 4.  New therapies, new concerns: rituximab-associated lung injury.

Authors:  Larry C Lands
Journal:  Pediatr Nephrol       Date:  2010-03-02       Impact factor: 3.714

5.  Severe respiratory adverse events associated with rituximab infusion.

Authors:  Koichi Kamei; Shuichi Ito; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-12-19       Impact factor: 3.714

6.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

Review 7.  Smart and genetically engineered biomaterials and drug delivery systems.

Authors:  Jindrich Kopecek
Journal:  Eur J Pharm Sci       Date:  2003-09       Impact factor: 4.384

8.  The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.

Authors:  Josee Golay; Elena Cittera; Nicola Di Gaetano; Massimiliano Manganini; Michela Mosca; Manuela Nebuloni; Nico van Rooijen; Luca Vago; Martino Introna
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

9.  Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

Authors:  Russell N Johnson; Pavla Kopecková; Jindrich Kopecek
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

10.  Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface.

Authors:  Kuangshi Wu; Jihua Liu; Russell N Johnson; Jiyuan Yang; Jindrich Kopecek
Journal:  Angew Chem Int Ed Engl       Date:  2010-02-15       Impact factor: 15.336

View more
  23 in total

1.  Immunogenicity of coiled-coil based drug-free macromolecular therapeutics.

Authors:  Miloslav Kverka; Jonathan M Hartley; Te-Wei Chu; Jiyuan Yang; Regina Heidchen; Jindřich Kopeček
Journal:  Biomaterials       Date:  2014-04-22       Impact factor: 12.479

2.  Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells.

Authors:  Te-Wei Chu; Ken M Kosak; Paul J Shami; Jindřich Kopeček
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

Review 3.  CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.

Authors:  Yaghoub Safdari; Vahideh Ahmadzadeh; Safar Farajnia
Journal:  Invest New Drugs       Date:  2016-04-13       Impact factor: 3.850

Review 4.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

5.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

6.  Tracking and quantifying polymer therapeutic distribution on a cellular level using 3D dSTORM.

Authors:  Jonathan M Hartley; Rui Zhang; Manasa Gudheti; Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2016-02-16       Impact factor: 9.776

7.  Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy.

Authors:  Huaizhong Pan; Monika Sima; Jiyuan Yang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2013-01-22       Impact factor: 4.979

Review 8.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

Review 9.  Polymeric drugs: Advances in the development of pharmacologically active polymers.

Authors:  Jing Li; Fei Yu; Yi Chen; David Oupický
Journal:  J Control Release       Date:  2015-09-26       Impact factor: 9.776

Review 10.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.